Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation.

Shah S, Brock EJ, Jackson RM, Ji K, Boerner JL, Sloane BF, Mattingly RR.

Neoplasia. 2018 Sep;20(9):951-963. doi: 10.1016/j.neo.2018.07.002. Epub 2018 Aug 22.

2.

Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.

Bao B, Mitrea C, Wijesinghe P, Marchetti L, Girsch E, Farr RL, Boerner JL, Mohammad R, Dyson G, Terlecky SR, Bollig-Fischer A.

Sci Rep. 2017 Mar 10;7:44125. doi: 10.1038/srep44125.

3.

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.

Linklater ES, Tovar EA, Essenburg CJ, Turner L, Madaj Z, Winn ME, Melnik MK, Korkaya H, Maroun CR, Christensen JG, Steensma MR, Boerner JL, Graveel CR.

Oncotarget. 2016 Oct 25;7(43):69903-69915. doi: 10.18632/oncotarget.12065.

4.

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.

LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, Smith D, Pilat MJ, Zhang J, Tolaney SM, Cleary JM, Chen AP, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero AM, Zhang Y, Ji J, Ferry-Galow K, Kinders RJ, Parchment RE, Shapiro GI.

Clin Cancer Res. 2016 Jul 1;22(13):3227-37. doi: 10.1158/1078-0432.CCR-15-0652. Epub 2016 Feb 3.

5.

Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.

Boerner JL, Nechiporchik N, Mueller KL, Polin L, Heilbrun L, Boerner SA, Zoratti GL, Stark K, LoRusso PM, Burger A.

PLoS One. 2015 Mar 16;10(3):e0119614. doi: 10.1371/journal.pone.0119614. eCollection 2015.

6.

Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.

Madden JM, Mueller KL, Bollig-Fischer A, Stemmer P, Mattingly RR, Boerner JL.

Breast Cancer Res Treat. 2014 Sep;147(2):283-93. doi: 10.1007/s10549-014-3102-8. Epub 2014 Aug 17.

7.

EGFR Tyrosine 845 Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer Cells Require Activation of p38 MAPK.

Mueller KL, Powell K, Madden JM, Eblen ST, Boerner JL.

Transl Oncol. 2012 Oct;5(5):327-34. Epub 2012 Oct 1.

8.

Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer.

Hou J, Wu J, Dombkowski A, Zhang K, Holowatyj A, Boerner JL, Yang ZQ.

Am J Transl Res. 2012;4(3):247-56. Epub 2012 Jul 22.

9.
10.

A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.

Giordano CR, Mueller KL, Terlecky LJ, Krentz KA, Bollig-Fischer A, Terlecky SR, Boerner JL.

Exp Cell Res. 2012 Oct 1;318(16):2014-21. doi: 10.1016/j.yexcr.2012.06.001. Epub 2012 Jun 8.

11.

Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.

Irwin ME, Bohin N, Boerner JL.

Cancer Biol Ther. 2011 Oct 15;12(8):718-26. doi: 10.4161/cbt.12.8.16907. Epub 2011 Oct 15.

12.

Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL.

J Cell Physiol. 2011 Sep;226(9):2316-28. doi: 10.1002/jcp.22570.

13.

EGFR/Met association regulates EGFR TKI resistance in breast cancer.

Mueller KL, Yang ZQ, Haddad R, Ethier SP, Boerner JL.

J Mol Signal. 2010 Jul 12;5:8. doi: 10.1186/1750-2187-5-8.

14.

Epidermal growth factor receptor translocation to the mitochondria: regulation and effect.

Demory ML, Boerner JL, Davidson R, Faust W, Miyake T, Lee I, Hüttemann M, Douglas R, Haddad G, Parsons SJ.

J Biol Chem. 2009 Dec 25;284(52):36592-604. doi: 10.1074/jbc.M109.000760. Epub 2009 Oct 19.

15.

RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.

Edwards H, Xie C, LaFiura KM, Dombkowski AA, Buck SA, Boerner JL, Taub JW, Matherly LH, Ge Y.

Blood. 2009 Sep 24;114(13):2744-52. doi: 10.1182/blood-2008-09-179812. Epub 2009 Jul 28.

16.

Role of Src family kinases in acquired resistance to EGFR therapies in cancer.

Boerner JL.

Cancer Biol Ther. 2009 Apr;8(8):704-6. No abstract available.

PMID:
19417559
17.

Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.

Mueller KL, Hunter LA, Ethier SP, Boerner JL.

Cancer Res. 2008 May 1;68(9):3314-22. doi: 10.1158/0008-5472.CAN-08-0132.

18.

Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells.

Streicher KL, Willmarth NE, Garcia J, Boerner JL, Dewey TG, Ethier SP.

Mol Cancer Res. 2007 Aug;5(8):847-61. Epub 2007 Aug 1.

19.

Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis.

Boerner JL, Biscardi JS, Silva CM, Parsons SJ.

Mol Carcinog. 2005 Dec;44(4):262-73.

PMID:
16167350
20.

Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells.

Boerner JL, Gibson MA, Fox EM, Posner ED, Parsons SJ, Silva CM, Shupnik MA.

Mol Endocrinol. 2005 Nov;19(11):2660-70. Epub 2005 Jun 23.

PMID:
15976008
21.
22.

Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis.

Boerner JL, Danielsen AJ, Lovejoy CA, Wang Z, Juneja SC, Faupel-Badger JM, Darce JR, Maihle NJ.

Oncogene. 2003 Oct 2;22(43):6679-89.

PMID:
14555981
23.

Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm.

Boerner JL, Danielsen A, Maihle NJ.

Exp Cell Res. 2003 Mar 10;284(1):111-21. Review.

PMID:
12648470
24.

STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor.

Kloth MT, Laughlin KK, Biscardi JS, Boerner JL, Parsons SJ, Silva CM.

J Biol Chem. 2003 Jan 17;278(3):1671-9. Epub 2002 Nov 11.

25.

Activation of Rho is required for ligand-independent oncogenic signaling by a mutant epidermal growth factor receptor.

Boerner JL, Danielsen A, McManus MJ, Maihle NJ.

J Biol Chem. 2001 Feb 2;276(5):3691-5. Epub 2000 Nov 10.

26.

An oncogenic epidermal growth factor receptor signals via a p21-activated kinase-caldesmon-myosin phosphotyrosine complex.

McManus MJ, Boerner JL, Danielsen AJ, Wang Z, Matsumura F, Maihle NJ.

J Biol Chem. 2000 Nov 10;275(45):35328-34.

27.

Ras-independent oncogenic transformation by an EGF-receptor mutant.

Boerner JL, McManus MJ, Martin GS, Maihle NJ.

J Cell Sci. 2000 Mar;113 ( Pt 6):935-42.

Supplemental Content

Loading ...
Support Center